Buy this Article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Eribulin mesylate (Halaven), a microtubule inhibitor, has been approved for the treatment of late-stage, metastatic breast cancer after other treatments have failed.

 

* Eribulin mesylate was found to prolong life in women with late-stage breast cancer.

 

* The drug can prolong the QT interval and shouldn't be given in combination with other drugs that do so.